We evaluated, by an improved susceptibility testing method, the prevalence and significance of low-level glycopeptide resistance in methicillin-resistant Staphylococcus aureus (MRSA) isolates, which belonged to a previously described, retrospective cohort of patients treated for orthopedic devicerelated infections (ODRI) at the Geneva University Hospital between 2000 and 2008. Fifty-seven individual or multiple isolates were retrieved from 41 ODRI patients for glycopeptide susceptibility and clonality studies, including 20 patients with prosthetic joint (PJ) and 21 with osteosynthesis (OS) MRSA infections. Low-level glycopeptide resistance was detected by elevated teicoplanin or/and vancomycin minimum inhibitory concentrations (MICs ≥4 mg/L), as determined by a previously validated combination of macrodilution and agar dilution assays of improved sensitivity. MRSA isolates with elevated teicoplanin MICs were detected in 20/41 (49 %) ODRI patients at the onset or during the course of glycopeptide therapy, namely, in 10 of 20 patients with PJ and 10 of 21 patients with OS infections. Only one isolate developed a concomitant increase in vancomycin MIC during therapy. 13/20 (65 %) glycopeptide-intermediate S. aureus (GISA)-infected patients, including 7/10 (70 %) with PJ and 6/10 (60 %) with OS, experienced treatment failure. In contrast, therapy failed in only 5/21 (24 %) ODRI patients with non-GISA isolates (p00.012), including 2/10 (20 %) with PJ and 3/11 (27 %) with OS infections. The emergence of low-level teicoplanin resistance could not be explained by teicoplanin administration, since only four patients received teicoplanin. The evaluation of
low-level teicoplanin resistance may improve the detection of GISA isolates. Further studies are warranted to evaluate the impact of low-level teicoplanin resistance on the outcome of glycopeptide therapy.
Introduction
Factors reported to increase the risk of glycopeptide treatment failure against invasive methicillin-resistant Staphylococcus aureus (MRSA) infections are: (1) the difficulty to reach adequate tissue levels at the true sites of MRSA infections, (2) the moderate bactericidal activity of glycopeptides, and (3) the emergence of glycopeptide resistance [1] [2] [3] [4] [5] [6] [7] [8] .
Phenotypic detection of vancomycin-intermediate S. aureus (VISA) isolates, which are defined by vancomycin minimum inhibitory concentration (MIC) breakpoints of ≥4 mg/L and <16 mg/L, and the absence of any vancomycin or teicoplanin resistance determinants (vanA, vanB, or vanC) found in vancomycin-resistant Enterococcus faecalis or high-level vancomycin-resistant (vancomycin MIC: 16 mg/L) S. aureus isolates (VRSA) [5] [6] [7] [8] [9] [10] [11] [12] is frequently problematic [1, 2, [4] [5] [6] [7] [8] .
Since VISA isolates are generally cross-resistant to teicoplanin [4, 13] , they are also designated glycopeptide-intermediate S. aureus (GISA). In contrast to vancomycin, teicoplanin susceptibility breakpoints in S. aureus vary from 2 mg/L by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) [14] to 8 mg/L by the Clinical and Laboratory Standards Institute (CLSI) [15] .
Detection of the GISA phenotype is particularly difficult for isolates displaying heterogeneous resistance to either or both glycopeptide(s) (hGISA), in which only a subset of the microbial population can express glycopeptide resistance [7, 9, [14] [15] [16] [17] [18] , and which are likely precursors of GISA isolates under the selective pressure of glycopeptides [6, 19] . The unsuccessful detection of hGISA isolates by standard microbiological methods has triggered the development of alternative assays, such as the modified population analysis profile (PAP) area under the curve (AUC), the Etest macromethod, and the glycopeptide resistance determination (GRD) test [6, 7, [20] [21] [22] .
The predictive value of vancomycin and teicoplanin susceptibility breakpoints on the outcome of glycopeptide therapy is still debated, despite their recent adjustment by the CLSI and EUCAST [8, 16] . While higher rates of vancomycin treatment failures were frequently reported in bacteremic patients infected with MRSA isolates for which vancomycin MICs were 2 mg/L, compared to those with lower vancomycin MICs (<2 mg/L) [1, 2, 8, 16, [23] [24] [25] [26] , as confirmed by a recent meta-analysis [27] , these data might be explained, at least in part, by the low sensitivity of some MIC testing methods, such as the broth microdilution and agar dilution assays, which lead to a significant underdetection of some GISA or hGISA isolates [28] [29] [30] .
While numerous studies evaluated the impact of glycopeptide MICs and low-level resistance on the outcome of glycopeptide therapy in MRSA bacteremic patients [5-8, 24-26, 31] , a single report linked the presence of GISA/ hGISA isolates with a negative outcome of vancomycin therapy for MRSA-infected, orthopedic patients [32] .
We recently reported a high prevalence of GISA isolates in patients with persistent or recurrent MRSA bacteremia [33] , in which low-level glycopeptide resistance was detected by elevated teicoplanin or/and vancomycin MICs (≥4 mg/L), as determined by a previously validated combination of macrodilution and agar dilution assays, allowing more sensitive detection of slow-growing, glycopeptide-"resistant" subpopulations [30] . Using this improved susceptibility testing method, we now present data on the prevalence and potential significance of low-level glycopeptide resistance in MRSA isolates from patients treated for orthopedic device-related infections (ODRI) at the Geneva University Hospital [34] .
Materials and methods

Clinical and microbiological data collection
Fifty-seven MRSA isolates from 41 patients with MRSA ODRI, who were treated at the Geneva University Hospital between 2000 and 2008, were routinely stored in skimmed milk/glycerol at −80°C [34] . These ODRI patients belonged to a retrospective cohort study, and their major clinical characteristics and risk factors for treatment failure have been previously described in detail [34] . MRSA isolates were essentially intra-operative specimens and aspirated synovial fluid [34] . In five patients, blood isolates that were clonally related to intra-operative isolates were also analyzed.
Twenty of the 41 ODRI patients had prosthetic joint (PJ) and 21 osteosynthesis (OS) MRSA infection [34] . MRSA infections were considered persistent if the patient's clinical status required further surgery 5 days after the initiation of antimicrobial therapy, with isolation of the same MRSA isolate by intra-operative specimen [34] . Recurrence was defined as resurgence of the infection with a clonally related MRSA isolate after the end of antimicrobial therapy [34] .
Determination of glycopeptide MICs
Vancomycin and teicoplanin MICs were determined by a slightly modified, previously described tube macrodilution assay, using cation-adjusted Mueller-Hinton broth and standardized inocula of 10 6 colony-forming units (CFU)/mL [30] . MIC endpoints were read after 48 h incubation at 37°C, to improve the detection of slow-growing, glycopeptide-"resistant" subpopulations [30] . This procedure was combined with a modified agar MIC testing method, which was used for confirmatory testing of glycopeptide MICs recorded by macrodilution, as previously described [30, 33] . In this modified agar MIC testing method, residual viable counts of each antibiotic-containing agar plate inoculated with ca. 10 6 CFU were scored after 48 h incubation at 37°C in a semiquantitative manner as confluent, semi-confluent, or ≤10 3 CFU, as previously described [30] . Glycopeptide MIC was defined as the lowest antibiotic concentration leading to a ≥99.9 % reduction in viable counts (≤10 3 CFU) on brain-heart infusion agar from the uniformly applied inoculum of 10 6 CFU, as previously described [30] .
To be scored as GISA, all MRSA isolates had to display elevated teicoplanin or/and vancomycin MICs (≥4 mg/L) by both modified macrodilution and agar testing assays [30, 33] .
Molecular typing
The clonality of consecutive MRSA isolates from patients with persistent or recurrent ODRI was assessed by a variable-number tandem repeat (VNTR) genotyping method [35] , as previously described [34] . Strain pairs with >85 % similarity in the dendrogram were considered to be clonally related (Bioanalyzer Experiments Clustering Software) [35] .
Statistical analyses
Microbiological, demographic, and clinical characteristics of GISA-and non-GISA-infected ODRI patients were compared by the Fisher's exact test for categorical variables or the Mann-Whitney test for continuous variables (http://vassarstats.net/). Relationships were considered to be significant when the two-sided p-value was ≤0.05.
Results
Prevalence of GISA in ODRI patients
MRSA isolates showing elevated teicoplanin MICs (≥4 mg/L) were detected in 20 (49 %) of the 41 ODRI patients, including 10 of 20 (50 %) PJ-infected and 10 of 21 (48 %) OS-infected patients. In contrast, none of the 41 ODRI pretherapy isolates displayed elevated vancomycin MICs (≥4 mg/L).
For two patients, teicoplanin MICs were 2 mg/L in pretherapy isolates and increased to 4 mg/L in subsequent isolates. For the remaining 18 patients, teicoplanin MICs were already elevated in pretherapy isolates and remained constant in subsequent isolates, except for two patients in whom teicoplanin MICs increased from 4 to 8 mg/L in consecutive isolates. In a single patient with low-level teicoplanin-resistant isolates, vancomycin MICs increased from 2 to 4 mg/L from baseline to subsequent isolates.
Clonality of GISA isolates in ODRI patients
All MRSA isolates with elevated teicoplanin MICs belonged to the hospital-acquired South German MRSA clone ST228 (SCCmec type 1 and agr type 2), which became predominant in our institution after 1998 [36] . This MRSA clone was previously reported to have infected 35 of the 41 ODRI patients (85 %) by spa and VNTR typing methods [34] . All available sequential isolates from patients with persistent or recurrent ODRI were clonally related (data not shown). In contrast, none of the six residual isolates belonging to other clonotypes (ST1, ST5, ST8, ST80, ST239), including other SSCmec (III, IV, V) and agr (1, 3) types [34] , exhibited low-level glycopeptide resistance. The prevalence of isolates displaying low-level glycopeptide resistance was significantly higher in the ST228 clonotype compared to other clonotypes (p00.021; Table 1 ).
Prevalence of GISA isolates and treatment outcomes in different subgroups of ODRI patients Thirteen of 20 GISA-infected ODRI patients (65 %) experienced MRSA-linked treatment failure compared to 5/21 (24 %) patients infected with non-GISA isolates (p00.012) ( Table 1) . Treatment failure was significantly (p00.032) higher in GISA-infected patients with persistent ODRI episodes compared to non-GISA isolates. There were also nonsignificant trends toward higher rates of recurrent ODRI episodes or multiple treatment failures in GISA-infected compared to non-GISA-infected patients.
Higher failure rates were observed in both subgroups of GISA-associated ODRI patients, namely, in 7/10 (70 %) PJ and 6/10 (60 %) OS patients, compared to 2/10 (20 %) PJ (p00.070) and 3/11 (27 %) OS patients with non-GISA infections (p00.198; Table 1 ). Higher treatment failure rates were recorded in GISA-compared to non-GISA-infected ODRI patients with implant retention, as well as in patients with implant removal (Table 1) , but these differences did not reach statistical significance due to the small sample sizes.
In brief, there was a consistent trend toward higher treatment failure rates in all subgroups of GISA-compared to non-GISA-infected ODRI patients.
Comparison of GISA-and non-GISA-infected patients
The major demographic and clinical characteristics of ODRItreated patients are presented in Table 2 . Noteworthy, GISAinfected patients were significantly younger (p00.037) than non-GISA-infected patients. While underlying conditions and rates of surgical debridement were similar in GISA-and non-GISA-infected patients, there was a trend for longer duration of hospital stay, which reached significance for the cumulated duration of hospital stay (p00.036) in GISA-versus non-GISA-infected patients. While the rates of bacteremic episodes concomitant to ODRI were not significantly different in GISAand non-GISA-infected patients, there was a non-significant trend (p00.180) for a higher overall mortality in GISAinfected (40 %; n08) compared to non-GISA-infected (19 %; n04) patients. Most of those deaths were unrelated to MRSAlinked ODRI or bacteremia. Only two GISA-infected patients died from MRSA-linked ODRI or bacteremia, but death occurred only 77 and 185 days, respectively, after ODRI onset.
Treatment modalities for GISA-and non-GISA-infected patients
The potential impact of therapeutic regimens on the treatment outcomes of GISA-compared to non-GISA-infected ODRI patients was evaluated. Besides one patient who was treated with trimethoprim-sulfamethoxazole, all other patients initially received intravenous regimens of vancomycin, either in monotherapy (n017) or combined with other agents (n023). Altogether, the administration of additional antibiotic regimens to ODRI patients after initial intravenous therapy led to a total of eight different antimicrobial regimens (Table 3 ). This great diversity and the small sample size in each group precluded any detailed comparison of the impact of each antimicrobial regimen on GISA-compared to non-GISA-infected ODRI patients.
There was a trend for higher failure rates recorded in GISA-infected patients (78 %) initially treated with vancomycin monotherapy (n09), with or without additional antimicrobial regimens, compared to the rate (38 %) in non-GISA-infected patients (n08), which did not reach significance (p00.153). In contrast, there were no significant differences in the daily doses and durations of antimicrobial regimens (data not shown) administered to GISA-versus non-GISA-infected patients.
Several regimens of combined therapy involving vancomycin associated with either rifampin, trimethoprim-sulfamethoxazole, or fusidic acid were administered to 23 ODRI patients ( Table 3 ). The impact of each therapeutic regimen on the outcome of GISA-versus non-GISA-infected ODRI patients could not be analyzed in detail due to low sample sizes. Interestingly, teicoplanin administration was shown to play no significant role in the presence of GISA isolates in ODRI patients. While only four ODRI patients received teicoplanin as subsequent antimicrobial therapy (Table 3) , none of these patients were infected with GISA isolates.
Discussion
Despite a continuously increasing number of clinical and microbiological reports, as summarized in [6, 7, 27] , the impact of low-level glycopeptide resistance on the outcome of GISA infections is still debated. This unclear situation mostly results from technical issues in characterizing the low-level glycopeptide resistance phenotype in MRSA isolates, which is frequently heterogeneous and, thus, escapes detection by standard MIC assays. Furthermore, there is no molecular assay for detecting low-level glycopeptide resistance, whose molecular basis is likely multifactorial and may even display some strain-specific variability [37] . While a recent meta-analysis supports the concept that slightly elevated vancomycin MICs, scored at the higher end of the susceptibility range by microdilution or Etest, were associated with worse outcomes of glycopeptide therapy in MRSA bloodstream infections, Two GISA and two non-GISAinfected patients received SXT and three non-GISA-infected patients received TEC c Two GISA and one non-GISAinfected patients received SXT, two GISA and eight non-GISAinfected patients RIF + fusidic acid, one non-GISA patient RIF + LZD, and one non-GISA patient received TEC the contribution of hGISA could not be evaluated in this context [27] .
To facilitate the detection of hGISA or GISA by standard MIC criteria, we developed a modified macrodilution MIC assay by using higher inocula than broth microdilution MIC and extending the incubation period to 48 h at 37°C, which is mandatory for detecting the slowly growing resistant subpopulations [30] . The increased sensitivities of the modified macrodilution assay combined with a modified agar MIC method markedly increased the detection rates of isolates with slightly elevated teicoplanin and vancomycin MICs (≥4 mg/L), by ca. 10-fold and 4-fold, respectively, compared to broth microdilution [30] . Most recently, the modified macrodilution MIC assay allowed detecting a higher prevalence of MRSA isolates with slightly elevated vancomycin or teicoplanin MICs in patients with persistent or recurrent episodes of MRSA bacteremia compared to those with single episodes [33] . Collectively, these data strongly suggest that a significant proportion of MRSA bloodstream isolates scored with slightly elevated vancomycin MICs (2 mg/L) by microdilution in previous studies [24, 27, 38] could have been undetected VISA or hVISA.
Since our previous contributions indicated that >95 % of isolates with elevated vancomycin MICs displayed crossresistance to teicoplanin, elevated teicoplanin MIC was considered to be a reliable marker of the GISA phenotype, which could facilitate the screening of isolates with lowlevel vancomycin resistance [13, 30] . Indeed, in our recent study of patients with persistent or recurrent episodes of MRSA bacteremia, 63 % of isolates displaying low-level resistance to teicoplanin were concomitantly resistant to vancomycin [33] .
In contrast to patients with MRSA bloodstream infections, vancomycin cross-resistance was a rare event in teicoplanin-resistant isolates from ODRI patients. Indeed, only one patient among all of the teicoplanin-resistant isolates detected in 20 patients displayed concomitant resistance to vancomycin. Noteworthy, teicoplanin-resistant isolates were already present in 90 % of GISA-infected ODRI patients at the onset of antimicrobial therapy, while the emergence of low-level teicoplanin resistance during therapy occurred in only 10 % of the patients. Remarkably, the administration of teicoplanin therapy was not associated with the emergence of low-level teicoplanin-resistant isolates, since none of the four teicoplanin-treated patients were infected with resistant isolates.
A most intriguing finding of this study was that ODRI patients infected with MRSA isolates displaying low-level teicoplanin resistance but still showing in vitro susceptibility to vancomycin seemed to respond poorly to antimicrobial regimens involving vancomycin compared to non-GISAinfected patients These observations lead us to speculate that in vivo conditions prevailing in ODRI patients might significantly alter the metabolic parameters of MRSA in such a way that teicoplanin resistance mechanisms may compromise MRSA susceptibility to vancomycin therapy. Previous studies performed in an animal model of chronic, implant-associated MRSA infection indicated a drastic loss of susceptibility to antibiotic killing in bacteria directly removed from infected foci [39] [40] [41] [42] . Other important parameters that may contribute to bacterial survival in MRSA chronic infections are intracellular persistence [43] , which may be further promoted by teicoplanin resistance determinants [44] , and bacterial adherence, leading to biofilm formation and colonization of artificial surfaces [41, 45, 46] . Recent molecular studies indicated that the emergence of vancomycin and teicoplanin endogenous resistance is likely a stepwise process involving several mutations in key regulatory genes [6, 13, 37] . While the molecular differences between isolates displaying combined low-level resistance to both teicoplanin and vancomycin versus those resistant to teicoplanin alone have not been elucidated, molecular studies performed in our laboratory suggest that resistance to teicoplanin alone might represent an early step of low-level glycopeptide resistance, which may eventually lead to vancomycin resistance via additional mutations [37] . In this context, the exclusive presence of GISA isolates in a single MRSA clonotype, namely, the South German clone ST228 or relatives, which became predominant in ODRI MRSA infections reported in our institution from 2000 to 2008 [34, 36] , as opposed to its absence in other clonotypes, is remarkable. It is possible that the ST228 clonal family, which is characterized by SCCmec type 1 and agr type 2, may contain some phenotypically silent mutations predisposing to the emergence of glycopeptide resistance.
The complexity of the clinical data, in particular, the high diversity of surgical procedures and antimicrobial regimens administered to ODRI patients, did not allow a detailed risk factor analysis of GISA-compared to non-GISA-infected ODRI patients. Our previous report analyzing the overall impact of antimicrobial therapy on the outcome of all MRSA-infected ODRI patients revealed the significant benefit on patient outcome of a combined rifampin-fusidic acid regimen administered after initial rifampin-vancomycin therapy [34] . Controlled trials involving larger groups of MRSA ODRI patients are needed in order to evaluate the efficacy of the rifampin-fusidic acid combination over other regimens, against GISA-as well as non-GISA-infected patients.
This study has some limitations. This was a single-center, retrospective cohort study, which required extended followup periods for the clinical and microbiological evaluations of ODRI patients. Failure of glycopeptide therapy in MRSA ODRI patients is clearly multifactorial, as found in several studies, being influenced by several demographic and clinical risk factors in addition to the emergence of reduced susceptibility to glycopeptides. The difficulty in recruiting adequate numbers of GISA-and non-GISA-infected ODRI patients for comparative studies leads to small sample sizes that prevent detailed analysis of risk factors. In some parts of our study, both OS and PJ patients with persistent and recurrent GISA ODRI episodes had to be analyzed collectively in view of the small numbers.
In conclusion, the development of simple, more sensitive MIC assays for detecting GISA isolates should prompt the development of a multicenter, prospective study for evaluating the impact of the GISA phenotype and clinical risk factors on the outcome of glycopeptide therapy in MRSA ODRI patients. In particular, multicenter controlled studies are needed so as to define the most adequate antibiotic regimen(s) for such infections.
